Last week, 10 science and tech startups participated in the ACE Venture Lab Bootcamp – an intensive training program for early-stage startups that offers unique workshops and mentoring from the best startup experts.
Here are the 10 teams that have successfully completed the Bootcamp and continued to the Validation program of ACE Venture Lab.
Zazu offers Emma and Ben, your AI-based, on-demand personal assistants who will take over the laborious e-mailing involved in scheduling meetings by scheduling them for you.
Smallcalc reduces large datasets 10 to 40 times in size, in order to increase their performance, and allow sharing compessed data between users and systems in a standard format.
SCITODATE provides tailored articles to all researchers who seek to stay up-to-date with minimal effort, through a daily scientific recommendation engine.
S2Credit is an online platform providing alternative finance solutions for individuals, to invest or save disposable income and get access to personal loans from the monetary contributions from a community.
Constelle allows for designing your software using best practices of modern software engineering – a design which is not just a drawing, but an executable that you can run and analyze.
aucbooks.com aims at facilitating textbook trade in student communities, by connecting students that don’t have a textbook to students that do, through a directory where buyer and seller can meet.
CityBreakers offers an online platform that builds on existing trusted sources for accommodation booking, tourist attractions and venues.
ourcity.guide helps hospitality brands to increase their customer’s experience and ensure guests to get the most out of their stay by offering curated digital city guides.
Move Metrics develops algorithmic solutions for movement data from sport or health applications and devices, in close collaboration with universities, companies, medical therapists and coaches to enhance personalized feedback.
Lars van der Heide and Marten Smidt are developing a drug to treat symptoms of Parkinson’s Disease by targeting an alternative, more specific pathway with less side-effects than current medication.